Seastar Medical Targets 2027 Completion for NEUTRALIZE-AKI Trial and Prepares PMA Submissions
Seastar Medical Holding Corporation (ICU) reported strong demand for its QUELIMMUNE product, particularly within the ultra-rare pediatric acute kidney injury (AKI) market. During the Q3 2026 earnings call, management highlighted new registry data that suggests statistically significant higher survival rates in patients treated with QUELIMMUNE. Looking ahead, the company is focused on its NEUTRALIZE-AKI clinical trial, with expectations to complete enrollment by midyear 2027. Seastar is also proactively preparing modular Premarket Approval (PMA) submissions to streamline future regulatory processes for its technologies.
Tickers: $ICU
Topics: clinical data earnings call pediatric AKI product demand